Lavipharm S.A (LAVI)
Athens Exchange · Greece · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 1.452 |
|---|---|
| 52-week range | 0.781 – 1.738 |
| Return, 1 month / 3 months | −8.0% / +2.8% |
| Return, 1 year / 3 years | +84.3% / +149.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 24 |
| Volatility (1 year) | 38.0% |
| Worst drawdown (1 year) | -25.5% |
| Average daily value traded | 0.13M EUR |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lavipharm is a Greek pharmaceutical company based in Athens. It develops, manufactures and markets medicines, with particular strength in transdermal patches and other controlled-release drug delivery systems made at its own production facilities. The company supplies prescription and over-the-counter products, including branded medicines and consumer health items, to pharmacies, hospitals and distributors in Greece and in export markets. Its work spans research and development, manufacturing and the commercial distribution of pharmaceutical products.
The shares are listed on the Athens Exchange in Greece under the code LAVI, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Lavipharm S.A (LAVI) trades on the Athens Exchange in Greece. It last closed at EUR 1.452 on 23 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 61 of 143 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 84.3% and over the last three months it rose 2.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Athens Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.4% | ||
| From 52-week high | -14.8% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 2.8% | ||
| 6-month return | 5.3% | ||
| 12-month return, skipping the last month | 100.3% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.5% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.13M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 15 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 2 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −3.7% |
|---|---|
| 1 month | −8.0% |
| 3 months | +2.8% |
| 6 months | +5.3% |
| 1 year | +84.3% |
| 3 years | +149.1% |
| 5 years | +35.1% |
Signals
| 50-day / 200-day average | 1.567 / 1.432 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.045 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Jul 2026 | EUR 0.0200 |
| 17 Jul 2025 | EUR 0.0200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Athens Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.